There’s something about intravitreal (IVT) injections that has a way of focusing the mind. Perhaps it’s the precision required, or the proximity to something as delicate as the retina, or the quiet understanding that when a therapy is delivered this way, there is very little room for improvisation. In today’s clinical trial landscape, IVT-based studies are becoming more and more common. And with them comes a new era of exacting standards, specialized expertise, and just a hint of high-stakes choreography. At Ora, we’ve had a front-row seat to this evolution, and let’s just say: when it comes to IVT trials, precision isn’t just preferred, it’s everything.
So why the increase in IVT-based studies? The answer lies in the innovation sweeping through ophthalmology. As therapies grow more sophisticated, so too do their delivery methods. We’re seeing a shift from subretinal approaches toward intravitreal vector delivery for gene therapies, offering less invasive access to the retina while still targeting complex diseases like inherited retinal disorders and geographic atrophy. At the same time, new advanced biologics are entering the clinical stage, many of them relying on IVT administration to reach their intended site of action. This evolution reflects an exciting reality: we’re no longer just managing disease; we’re attempting to modify, repair, and even regenerate. Naturally, that raises the bar for how these trials are conducted.
Delivering an intravitreal injection in a controlled, clinical setting may be routine in practice. But delivering it consistently across a global clinical trial? That’s where things get interesting.
Protocols for IVT studies are often highly specified, down to the angle of injection, the quadrant of entry, the handling of the investigational product, and post-injection monitoring. Variability isn’t just inconvenient; it can impact safety, efficacy, and ultimately trial outcomes. This is why site selection becomes paramount. Not every site is equipped for this level of precision; it requires experienced investigators, well-trained staff, and an infrastructure that supports both procedural rigor and patient safety. In IVT trials, the right hands truly matter.
Of course, precision doesn’t stop at the injection. It begins long before, with finding the right patients. Many of these studies are small by design, focused on highly specific populations with narrowly defined eligibility criteria. Whether it’s a particular stage of geographic atrophy, a genetic subtype of inherited retinal disease, or a defined progression profile in dry AMD, the margin for error in patient selection is slim. Recruitment becomes a thoughtful exercise in alignment: matching the right patient to the right protocol at the right time. It’s a bit like assembling a very particular puzzle, where every piece must fit just so and there aren’t many extra pieces lying around.
This is where experience and coordination make all the difference. At Ora, we’ve built a track record of delivering across these complex programs, whether small, highly specialized studies or expansive global trials spanning multiple regions and regulatory environments. Our teams have supported dry AMD, inherited retinal disease, geographic atrophy, diabetic macular edema, glaucoma, and wet AMD programs involving both intravitreal and systemically administered therapies, adapting to a wide range of mechanisms of action and study designs. That breadth of experience allows us to anticipate challenges, standardize processes, and maintain the consistency that these trials demand site to site, patient to patient, and injection to injection.
Perhaps that’s the real story here. IVT trials may be complex, but they are also a testament to how far the field has come. We are venturing into therapies that were once the realm of imagination, and doing so with increasing confidence and capability. But as the science advances, so too must our approach to execution. Precision in site selection, rigor in protocol adherence, and care in patient identification are no longer optional; they are foundational.
Because when the treatment is delivered in microliters, every detail matters. Eye think… that’s a responsibility we’re ready to meet with steady hands, sharp focus, and a clear vision of what’s possible.